Summary & Overview
HCPCS J0485: Belatacept injection, 1 mg
HCPCS Level II code J0485 denotes the injection of belatacept, 1 mg, an intravenous immunosuppressive agent used primarily to prevent organ transplant rejection. Nationally, billing for transplant-related biologics like belatacept is significant because of high per-dose drug cost, site-of-service implications, and specialized administration requirements. Payers commonly involved in coverage and reimbursement for this therapy include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will find a compact briefing on what J0485 represents clinically and operationally, how it is reported on medical claims, and the typical settings where it is administered. The publication also outlines expected benchmarking topics such as utilization patterns, payment benchmarks, site-of-service impact on costs, and relevant policy considerations affecting outpatient infusion and transplant drug coverage. Where specific payer policies and benchmarks are not available from the input, the piece notes that data are not provided.
Billing Code Overview
HCPCS Level II code J0485 describes the injection of belatacept, 1 mg. This code represents a biologic immunosuppressive agent administered by intravenous infusion for prevention of organ transplant rejection.
-
Service type: Intravenous infusion medication administration
-
Typical site of service: Hospital outpatient infusion center, ambulatory infusion center, or transplant clinic infusion suite
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 52-year-old female kidney transplant recipient presents to the outpatient infusion clinic for maintenance immunosuppression with intravenous belatacept. The patient previously received induction therapy and has demonstrated early signs of calcineurin inhibitor–related nephrotoxicity, so the transplant team transitioned her to belatacept to preserve graft function. The clinic nurse verifies identity, reviews the patient’s weight and recent labs (including serum creatinine and complete blood count), confirms no active infections or recent vaccinations that would contraindicate therapy, and prepares the dose using J0485 (injection, belatacept, 1 mg) multiplied by the required milligram dose. A renal transplant specialist (nephrologist) documents the medical necessity and treatment plan; the infusion is administered via peripheral IV over the recommended infusion time with monitoring for infusion reactions. Post-infusion, the patient is observed for the institution’s standard monitoring period, counseled on infection precautions, and scheduled for the next belatacept dosing visit per the regimen (monthly maintenance or as clinically indicated). Documentation includes indication, dose (number of milligrams and units of J0485 billed), lot number, route, site, start/stop times, and any adverse events.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW |